Posted by Michael Wonder on 26 Apr 2017
Tesaro announces approval of Varuby (oral rolapitant tablets) by European Commission
26 April 2017 - Commercial launches to begin on a country-by-country basis in Europe by end of Q2.
Tesaro today announced that the European Commission has approved Varuby (oral rolapitant tablets) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
Chemotherapy-induced nausea and vomiting is a frequent and debilitating, yet often preventable, side effect of chemotherapy.
Oral rolapitant was approved by the U.S. FDA on 1 September 2015 and is marketed by Tesaro in the United States under the brand name Varubi.
